Jintropin (recombinant human growth hormone) / GeneScience - LARVOL DELTA

A Study (Phase 1b/2) of GS3-007a Oral Treatment in Children With Growth Hormone Deficiency (PGHD) (clinicaltrials.gov) - P1/2 | N=88 | Recruiting | Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Endocrine Disorders • Growth Hormone Deficiency • Growth Hormone Deficiency (Pediatric) • Pediatrics • IGF1

A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Children With Achondroplasia (clinicaltrials.gov) - P4 | N=39 | Completed | Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. | Recruiting ➔ Completed | Trial completion date: Feb 2025 ➔ Dec 2025 | Trial primary completion date: Feb 2025 ➔ Aug 2025

Trial completion • Trial completion date • Trial primary completion date • Genetic Disorders • IGF1

Phase IV Study of rhGH Injection in Adult Short Bowel Syndrome (clinicaltrials.gov) - P4 | N=100 | Recruiting | Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.

New P4 trial • Gastrointestinal Disorder • Short Bowel Syndrome

Gensci134, A Long-Acting GHR-Agonistic VHH-Fc Fusion Protein, Demonstrates Sustained GH-Mimetic Activity and Enhanced Metabolic and Skeletal Effects in Preclinical Models (ENDO 2026) - "Adult and juvenile animals were treated with GenSci134 and compared with short-acting recombinant human GH (rhGH) and long-acting PEG-rhGH...These results suggest that GenSci134 has the potential to be an optimal therapeutic option for GHD patients. GenSci134 is currently being evaluated for its safety, tolerability, PK/PD profiles, and immunogenicity in healthy adult males via single subcutaneous injection."

Preclinical • Endocrine Disorders • Growth Hormone Deficiency • Growth Hormone Deficiency (Adult) • Growth Hormone Deficiency (Pediatric) • Metabolic Disorders • IGF1 • IGFBP3

A Clinical Study of GenSci134 in Healthy Adults and Adult Growth Hormone Deficiency(AGHD) (clinicaltrials.gov) - P1 | N=64 | Recruiting | Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. | Trial completion date: Apr 2026 ➔ Nov 2026 | Trial primary completion date: Apr 2026 ➔ Nov 2026

Trial completion date • Trial primary completion date • Endocrine Disorders • Growth Hormone Deficiency • Growth Hormone Deficiency (Adult) • IGF1

A Study of GenSci134 in Children With Growth Hormone Deficiency (PGHD) (clinicaltrials.gov) - P1/2 | N=128 | Not yet recruiting | Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.

New P1/2 trial • Endocrine Disorders • Growth Hormone Deficiency • Growth Hormone Deficiency (Pediatric) • Pediatrics • IGF1

A Study (Phase 1b/2) of GenSci134 in Children With Idiopathic Short Stature (ISS) (clinicaltrials.gov) - P1/2 | N=128 | Not yet recruiting | Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.

New P1/2 trial • Idiopathic Short Stature

A Study (Phase 1b/2) of GS3-007a Oral Treatment in Children With Growth Hormone Deficiency (PGHD) (clinicaltrials.gov) - P1/2 | N=88 | Not yet recruiting | Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.

New P1/2 trial • Endocrine Disorders • Growth Hormone Deficiency • Growth Hormone Deficiency (Pediatric) • Pediatrics • IGF1

A Phase II Study of PEG-rhGH Injection for Short Children Born Small for Gestational Age: Efficacy, Safety, and Pharmacokinetics (clinicaltrials.gov) - P2 | N=72 | Recruiting | Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.

New P2 trial • Small for Gestational Age

An Observational Study on the Height-Growth Effect of Pegylated Recombinant Human Growth Hormone in Genet (ChiCTR) - P4 | N=50 | Not yet recruiting | Sponsor: The People's Hospital of Guang'an District, Guang'an City; The People's Hospital of Guang'an District, Guang'an City

New P4 trial • IGF1

Efficacy And Safety Of Weekly PEGylated Recombinant Human Growth Hormone (Jintrolong) In Prepubertal Children With Turner Syndrome: 3-year Results From A Multicenter, Randomized Study In China (ENDO 2025) - P2 | "Objective: To evaluate the efficacy and safety of weekly PEGylated recombinant human growth hormone (PEG-rhGH, Jintrolong) over 3-year in prepubertal children with Turner Syndrome (TS). This multicenter, randomized, negative-controlled phase 2 study (NCT03189160) included a 52-week main phase followed by an ongoing open-label extension... Weekly Jintrolong at 0.1 to 0.4 mg/kg/week provided sustained and clinically meaningful growth improvements over 3 years in girls with TS. Most patients required dose escalation after the first year to achieve optimal growth velocity. This dosing range was appropriate for most patients and associated with a favorable long-term safety profile."

Clinical • Late-breaking abstract • Genetic Disorders • Turners Syndrome • IGF1

A Bioequivalence Study of Two Different PEG-rhGH Preparations (clinicaltrials.gov) - P1 | N=87 | Completed | Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. | Active, not recruiting ➔ Completed

Trial completion • Endocrine Disorders • Growth Hormone Deficiency • Growth Hormone Deficiency (Adult) • Growth Hormone Deficiency (Pediatric) • Pediatrics

A Clinical Study of GenSci134 in Healthy Male Adults (clinicaltrials.gov) - P1 | N=64 | Recruiting | Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open

A Clinical Study of GenSci134 in Healthy Male Adults (clinicaltrials.gov) - P1 | N=64 | Not yet recruiting | Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.

New P1 trial

Long-acting PEGylated Recombinant Human Growth Hormone (Jintrolong) in Short Children Born Small for Gestational Age: 4-Year Results from a Multicenter, Randomized, Dose-Response Trial in China (ESPE-ESE 2025) - P2 | "Our 4-year data show that long-term continuous Jintrolong PEG-rhGH treatment at an initial dose of 0.2 mg/kg/week, up to a maximum of 0.4 mg/kg/week in short children born SGA results in a normalization of height during childhood followed by growth along the target height SDS."

Clinical • Growth Hormone Deficiency • Growth Hormone Deficiency (Adult) • Small for Gestational Age • IGF1

A Bioequivalence Study of Two Different PEG-rhGH Preparations (clinicaltrials.gov) - P1 | N=87 | Active, not recruiting | Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Active, not recruiting

Enrollment closed • Endocrine Disorders • Growth Hormone Deficiency • Growth Hormone Deficiency (Adult) • Growth Hormone Deficiency (Pediatric) • Pediatrics

A Bioavailability Study of Two Different PEG-rhGH Preparations. (clinicaltrials.gov) - P1 | N=16 | Completed | Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Completed | Trial completion date: Dec 2024 ➔ Mar 2025

Trial completion • Trial completion date • Endocrine Disorders • Growth Hormone Deficiency • Growth Hormone Deficiency (Adult) • Growth Hormone Deficiency (Pediatric) • Pediatrics • IGF1

A Clinical Trial to Compare Pharmacokinetics of Two Different PEG-rhGH Preparations (clinicaltrials.gov) - P1 | N=48 | Completed | Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Completed

Trial completion • Endocrine Disorders • Growth Hormone Deficiency • Growth Hormone Deficiency (Adult) • Growth Hormone Deficiency (Pediatric) • Pediatrics

A Clinical Trail to Compare Pharmacokinetics of Two PEG-rhGH Injections With Different Preparations (clinicaltrials.gov) - P1 | N=60 | Completed | Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Completed

Trial completion • Endocrine Disorders • Growth Hormone Deficiency • Growth Hormone Deficiency (Adult) • Growth Hormone Deficiency (Pediatric) • Pediatrics

A Bioequivalence Study of Two Different Processes of PEG-rhGH Preparations (clinicaltrials.gov) - P1 | N=87 | Not yet recruiting | Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.

New P1 trial • Endocrine Disorders • Growth Hormone Deficiency • Growth Hormone Deficiency (Adult) • Growth Hormone Deficiency (Pediatric) • Pediatrics

A Bioequivalence Study of Two Different PEG-rhGH Preparations (clinicaltrials.gov) - P1 | N=87 | Not yet recruiting | Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.

New P1 trial • Endocrine Disorders • Growth Hormone Deficiency • Growth Hormone Deficiency (Adult) • Growth Hormone Deficiency (Pediatric) • Pediatrics

Real world study of PEG-rhGH treatment for growth hormone deficiency patients in Western China (ChiCTR) - P4 | N=1000 | Sponsor: Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China; Chengdu Women's and Chi

New P4 trial • Endocrine Disorders • Growth Hormone Deficiency • IGF1

A Real-world Study of Long-acting Growth Hormone Injection for Turner Syndrome (clinicaltrials.gov) - P=N/A | N=743 | Completed | Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.

New trial • Real-world • Real-world evidence • Genetic Disorders • Turners Syndrome

A Bioequivalence Study of Two Different PEG-rhGH Preparations. (clinicaltrials.gov) - P1 | N=87 | Completed | Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Completed | Trial completion date: Nov 2024 ➔ Aug 2024

Trial completion • Trial completion date • Endocrine Disorders • Growth Hormone Deficiency • Growth Hormone Deficiency (Adult) • Growth Hormone Deficiency (Pediatric) • Pediatrics

A Study on the Efficacy and Safety of Pegylated Recombinant Human Growth Hormone (Jintrolong®) in Children with Idiopathic Short Stature (ChiCTR) - P4 | N=100 | Not yet recruiting | Sponsor: Children's Hospital,Zhejiang University School of Medicine; Children's Hospital,Zhejiang University School of Medicine

New P4 trial • Idiopathic Short Stature